The company said on LinkedIn that it completed its minimum viable product (MVP) for the U-Pump system. It designed its patch pump to address affordability, precision and ease of use in insulin therapy.

Currently, Insulet leads the way in the patch pump space with its Omnipod platform of pumps. The market also has expected entries from Medtronic and Tandem Diabetes Care in the future. PharmaSens also submitted a patch pump to the FDA last year, while Luna Diabetes last year launched a pivotal trial for its automated patch pump system. Modular Medical offers its own patch pump that isn’t automated and Embecta won an FDA nod for its own open-loop patch pump, but discontinued the program not long after.

U-Pump says it designed its system to address affordability, precision and ease of use. It features OneMove technology, with a painless, one-step application, no tubes and no setup hassle. The company says on LinkedIn that its system also has “seamless CGM integration” and is “fully compatible” with leading Dexcom and Abbott systems.